Summary of Key Points
Recently, there have been three consecutive deaths in clinical trials initiated by researchers (IITs) in China: the CAR-T therapy from RiboX, the gene editing treatment at Xinhua Hospital, and the Duchenne muscular dystrophy treatment from Huida Gene. All these incidents were concealed until they were exposed by foreign media. The real issue is not the risks associated with the cutting-edge therapies themselves, but the concealment of information, which has sparked a crisis in trust regarding the quality of clinical trials and the regulatory system for innovative drugs in China, both domestically and internationally. Although new regulations have been introduced to govern IITs, the industry must return to the fundamental principle of "respecting life" and balance speed with safety.
Detailed Analysis
1. Understanding IITs: What are they, and why are they fast but risky?
IITs, or "Investigator-Initiated Trials," refer to trials led by doctors or researchers themselves, rather than being sponsored by pharmaceutical companies. These trials are overseen by the National Health Commission and conducted under the framework of medical technology research, without following the strict approval processes of drug regulatory agencies.
Why are IITs popular? They are faster and cost-effective, allowing for the rapid verification of the safety and efficacy of drugs, especially for cutting-edge therapies such as cell and gene therapies. This enables companies or researchers to obtain early data more quickly, making it easier to publish papers and apply for higher-level approvals (such as from the US FDA). In the past decade, 95% of cell/gene therapy studies published in top Chinese journals were IITs, highlighting their importance.
However, this comes with risks. The regulation of IITs is relatively lax, and patients participating in these trials bear greater risks due to the lack of strict oversight by drug regulatory agencies. This may lead to issues with trial design, drug quality, and risk management.
2. The worst part is the concealment: How were these incidents hidden?
The risk associated with cutting-edge therapies means that death events alone might not be the biggest problem; it's the failure to report them that has caused a public outcry:
- RiboX incident: A patient with scleroderma in their 50s died, but there was no public information in China. The event was only mentioned in documents submitted to the US FDA, and it became known only after foreign media exposure.
- Xinhua Hospital incident: A 6-year-old girl died in March 2025, but the research team published a paper in February 2026 focusing on mouse data, with no mention of the human death. The truth was revealed only after the publication in *Science*.
- Huida Gene incident: The company acknowledged the death a year later, after foreign media investigations. They had previously showcased early data but then stopped providing any further updates.
This concealment has used the academic and commercial hype as a cover for their mistakes, keeping patient families in the dark and eroding public trust in clinical trials.
3. A crisis of trust: Doubts from abroad and risks to cooperation
These incidents have raised doubts among international media and organizations:
- Public opinion: Foreign media are questioning the credibility of China's IIT regulatory system and using these cases to criticize the quality of Chinese clinical trials.
- Impact on international cooperation: Many multinational pharmaceutical companies were considering leveraging China's low-cost, high-efficiency clinical resources, but now the increased uncertainty may deter them from cooperating.
- Data recognition issues: The US already has biases regarding Chinese clinical data (doubting its integrity and ethics), and these incidents provide additional reasons to limit the acceptance of such data by the FDA, potentially blocking the path for Chinese innovative drugs to enter international markets.
4. Regulation has stepped in, but respect for life is essential
Regulatory measures have been implemented, with the "Regulations on Clinical Research of New Biomedical Technologies" coming into effect in May 2026, setting strict rules for IITs:
- Trials can only be conducted at top-tier hospitals.
- Safety and efficacy must be proven in animal studies before human trials begin.
- Gene therapy drugs must meet GMP (Good Manufacturing Practice) standards.
- Serious adverse events (such as deaths) must be reported within 5 days, and the trial must be paused.
However, rules are just the minimum requirement. The true key is to prioritize patient safety. The speed of IITs should not come at the expense of patient well-being. The purpose of these trials is to benefit patients sooner, not to provide shortcuts for companies or researchers. If we do not respect life, the industry will eventually fail.
5. IITs will not disappear, but they need to slow down and follow the rules
IITs are an important tool for the early validation of innovative drugs in China, especially for cutting-edge therapies. However, adjustments are necessary:
- Researchers and companies must prioritize patient safety and no longer conceal adverse events.
- Regulatory authorities must enforce these rules effectively to prevent them from becoming mere formality.
- Patients should be more cautious and understand the risks and data disclosure processes before participating in IITs.
Ultimately, the trust crisis surrounding Chinese innovative drugs depends on the joint efforts of regulators, companies, researchers, and patients. Without the respect of all parties, this path to success will not be sustainable.
Conclusion
Cutting-edge therapies can be developed quickly, but they must not be unregulated; trials can be innovative, but they cannot lose their ethical foundation. Only by putting patient safety first can Chinese innovative drugs truly achieve long-term success and reliability.